The role of the CD200-CD200R pathway in human sepsis-associated immunoparalysis (SIMPA study)
- Conditions
- blood poisoningsepsis1002766510004018
- Registration Number
- NL-OMON48977
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 35
- newly diagnosed sepsis as defined in the protocol
- 18 years or older
- able to understand the study information and sign an informed consent (as an
alternative, the presence of a representative that is able to understand the
study information and sign an informed consent)
- willing and according to the investigator able to follow the study procedures
- immunosuppressive therapy before admission to the ICU and thus before blood
can
be drawn
- pregnancy
- lactation
- known active HIV, HBV or HCV infection
- continuous venovenous hemofiltration (CVVH)
- coagulation disorder
- mechanical ventilation at home
- inclusion in a clinical intervention trial in which the intervention may
reasonably interfere with the outcomes of this study
- admission for more than two weeks on the wards prior to IC admission
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>- cytokine / inflammatory mediator (protein) concentrations (a.o. TNF-a, IL-1β,<br /><br>IL-6, IL-12, IFN-γ, IL-8, IL-10 and TFG-β) after ex vivo stimulation (with and<br /><br>without a CD200 axis (ant)agonist)<br /><br>- mRNA cytokine / inflammatory mediator expression (a.o. TNF-a, IL-1β, IL-6,<br /><br>IL-12, IFN-γ, IL-8, IL-10 and TGF-β) after ex vivo stimulation (with and<br /><br>without a CD200 axis (ant)agonist)</p><br>
- Secondary Outcome Measures
Name Time Method <p>1)<br /><br>- cell surface expression of immune receptors as CD200R, CD200 by direct flow<br /><br>cytometry (protein level) (in sepsis patients VS healthy controls)<br /><br>- mRNA expression of immune receptors as CD200R, CD200 (in sepsis patients VS<br /><br>healthy controls)<br /><br>- to determine the causing or contributing factors that alter the expression<br /><br>(a.o. signalling pathways)<br /><br>- cytokine / inflammatory mediator (protein) blood concentrations (a.o. TNF-a,<br /><br>IL-1β, IL-6, IL-12, IFN-γ, IL-8, IL-10 and TFG-β)<br /><br><br /><br><br /><br>2) correlation between CD200(R) expression and SOFA score, CD200R expression<br /><br>levels in survivors and non-survivors</p><br>